Physician profile
Mark Vellek
NPI 1063409688
$4,538.52
in general payments reported to CMS, 2019-2025
51 companies · $1,636 in 2025
The $1,636 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $474 · 2021: $127 · 2022: $114 · 2023: $323 · 2024: $1,115 · 2025: $1,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,023 · Education: $51.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,022.54 |
| Education | $51.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $464.76 | 2019-2025 | |
| Janssen Biotech, INC. | $397.49 | 2019-2025 | Erleada, Darzalex, Imbruvica |
| Astrazeneca Pharmaceuticals Lp | $389.38 | 2019-2025 | Enhertu, Imfinzi, Tagrisso |
| Pfizer INC. | $349.03 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $327.06 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech USA, INC. | $203.62 | 2019-2025 | Polivy, Phesgo, Perjeta |
| Abbvie INC. | $186.34 | 2024-2025 | |
| Genzyme Corporation | $131.62 | 2019-2025 | |
| Gilead Sciences, INC. | $130.83 | 2019-2025 | Trodelvy |
| Roche Diagnostics Corporation | $120.55 | 2020 | |
| Celgene Corporation | $118.27 | 2019-2025 | Reblozyl, Breyanzi, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $116.40 | 2024-2025 | Opdivo, Opdualag |
| Eisai INC. | $113.45 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $113.27 | 2024-2025 | Libtayo |
| Incyte Corporation | $108.69 | 2020-2025 | Jakafi |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vellek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.